In the European Union, neratinib was approved in 2018 as extended adjuvant treatment of adult patients with early‐stage hormone receptor‐positive HER2‐positive breast cancer (BC) who completed adjuvant trastuzumab‐based therapy less than 1 year previously (European Medicines Agency, 2022). Here, NR4A1 is linked to breast cancer.